Cyclo Therapeutics, Inc. (CYTH) reported Q2 EPS of ($0.41), $0.07 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $542 thousand versus the consensus estimate of $571 thousand.
Cyclo Therapeutics, Inc. (CYTH) reported Q2 EPS of ($0.41), $0.07 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $542 thousand versus the consensus estimate of $571 thousand.